Arena Pharma (ARNA) Misses Q3 EPS by 68c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Arena Reports Third Quarter Financial Results and Key Program Updates
November 4, 2021 4:05 PM EDTÂ Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout
 First participant randomized in the Phase 2 trial for temanogrel in Raynauds phenomenon secondary to systemic sclerosis
 Strong liquidity position to support continued pipeline progress
PARK CITY, Utah--(BUSINESS WIRE)-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
During the quarter, the team continued to make significant progress across all key programs, including... More
